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Abstract
Background: Maggot therapy has been in practice for effective debridement, disinfection and healing of chronic
wounds. Due to their antiseptic action during wound healing, their metabolites have been investigated in the past
for antibacterial activity. They have been particularly useful for treatment of wounds infected with multi-drug
resistant Staphylococcus aureus. Antibiotics, on the other hand, can predispose bacteria to develop resistance.
Substances that are able to modulate or delay the occurrence of resistance in bacteria are under investigation by
many researchers around the world. In the present study, antibacterial activity in excretions/secretions (ES) from
maggots of Lucilia cuprina blowfly was demonstrated. The extracts were also screened in combination with
antibiotic, ciprofloxacin.
Methods: L. cuprina blowfly maggots were reared for extraction of its metabolites. The ES extracted was screened
against S. aureus, alone and in combination with ciprofloxacin, both for short term and long term exposure
analysis. A microchannel-based device and system was used for experiments instead of conventional techniques.
Results: The original ES had shown partial bacterial growth inhibition. However, in combination with ciprofloxacin,
at sub-inhibitory concentrations, certain combinations revealed anti-staphylococcal activity, with bacterial reduction
of up to 50%, after 24 hours. The six day study on S. aureus exposed to ES-ciprofloxacin combination suggested a
potential delay in development of adaptive resistance as opposed to when ciprofloxacin was used as single agent.
Conclusions: The combination effect of ES and ciprofloxacin at sub-MIC levels showed enhanced antibacterial
activity compared to the effect of ES and ciprofloxacin as single agents. Based on the results of ES-ciprofloxacin
combinations, a more effective means of treatment for S. aureus can be proposed.
Background
Maggot therapy has been traditionally practiced for deb-
ridement of necrotic wounds as well as for curing bac-
terial infections at the wounds site [1,2]. It has been
reported to have advantages over the conventional
methods, especially for treatment of wounds infected by
multi-drug resistant methecillin-resistant Staphylococcus
aureus (S. aureus) or MRSA [3-8]. Their antiseptic
action has been investigated by many researchers in the
past for specialized antibacterial properties or presence
of antimicrobial factor(s). In particular, it has been
under investigation since 1930s. Simmons et. al. [9,10],
first studied the mechanism of action of maggot disin-
fection on wounds. They found that the excretion of
maggots exhibited a strong and rapid disinfection action
on S. aureus. Subsequently, several other groups col-
lected the excretions/secretions (ES) of maggots and
screened it on various microbes [11-15]. Many species
of blowfly maggots were investigated against both gram-
negative and gram-positive bacteria [11,12,16]. However,
most of these investigations were carried out using the
maggot of Lucilia sericata, a species of blowfly used for
maggot therapy in Europe and Americas. For the pre-
sent study, investigations were performed on ES
e x t r a c t e df r o mm a g g o t so fLucilia cuprina,a c q u i r e di n
Singapore.
The disinfection action of the maggots was suggested
by some to be present in the excretions from the mag-
gots [9,14], while others reported ingestion and gut
activity [17]. Recently, a low molecular weight insect
peptide was found mainly responsible for the antimicro-
bial activity of the maggots, when exposed to an
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fencin, that belongs to the insect antimicrobial peptides
(AMP), defensin family, was reported to be secreted in
the hemolymph, body fat and ES of the maggots. The
maggots were raised in an environment simulating a
wound that increased the production of the AMP as an
innate immune response of the insect [18,19].
The antibacterial activity of L. cuprina maggot ES was
previously shown to have partial growth inhibition of
gram-positive, S. aureus [20]. In the present study, the
maggot ES was analysed for presence of an antibacterial
factor using gas chromatography-mass spectrometry (GC-
MS) and pH test. Furthermore, with an aim to enhance
antibacterial activity, ES extractions were combined with
ciprofloxacin at sub-minimum inhibitory concentration
(MIC) levels and screened against S. aureus. Ciprofloxacin
is a broad spectrum fluroquinolone antibiotic, commonly
used for treatment of bacterial infections. There have been
a number of instances of increasing ciprofloxacin resis-
tance in S. aureus reported in the past [21,22]. The combi-
nation investigations of the antibiotic with natural extracts
of the insect was performed over an extended period of
time, to study their effects on the rapid adaptive resistance
in S. aureus for ciprofloxacin. The experiments were car-
ried out on a microchannel-device and a tailored monitor-
ing system [23].
Materials and methods
Experimental Set-up
A microfluidic device designed, fabricated and tested for
the purpose of drug-mixing and cell culturing was used
for the study [23]. The mixing of fluids was based on spe-
cialized microchannel geometry. Passive mixing occurred
at the wells where the cells were cultured. A system to
provide favourable environmental conditions and to
monitor cell behaviour was also used along with the
device. The incubator incorporated in the system
was able to maintain a temperature of 37 ± 0.2°C
for extended periods of time. The design principles and
testing of the experimental setup has been described
previously [23].
Bacterial strain and media
Gram-positive Staphylococcus aureus American Type
Culture Collection (ATCC) 29213 (methecillin-sensitive
S. aureus or MSSA), acquired from ATCC was used for
the experiments. The strain was stored in Luria broth
containing glycerol (40% v/v) at -80°C. Experimental
inocula and stocks were prepared in Iso-sensitist (IS)
broth and agar, respectively, acquired from Oxoid (Sin-
gapore). The stocks were subsequently stored at 4°C for
up to six weeks. For preparation of the maggot ES,
phosphate buffer saline (PBS) obtained from Biomedia
(Singapore) was used as the medium.
Antibiotics and MIC determination
Ciprofloxacin (99% purity) obtained from Sigma-Aldrich
(Singapore) was used for the experiments. Stock solution
with concentration 10 mg/mL of the antibiotic was pre-
pared in sterile deionized water (DI) with 0.1 M NaOH
to aid dilution. Aliquots of the stock were prepared and
stored at -20°C for further use. On the day of experi-
ment, working solution of the antibiotic was prepared
by diluting the stock solution with sterile PBS as media.
The MIC of the antibiotic was determined by the
broth microdilution method, explained elsewhere
[24,25]. Briefly, concentrations with a starting range of
128 μg/mL to 0.0625 μg/mL of the antibiotic was pre-
pared in wells of a 96-well plate in triplicates (Greiner
Bio one, Singapore), and bacterial inoculum were added
to this 2-fold dilution series. The plate was incubated at
37°C aerobically for 24 hours. The MIC was then deter-
mined as the minimum concentration of the antibiotic
in serially diluted assay with no visible bacterial growth.
This was re-confirmed in a spectrometer at 600 nm
wavelength incident light.
Maggot ES extraction, analysis and MIC determination
The various techniques used to extract the ES or useful
antibacterial extracts from the maggots of L. cuprina
were previously compared and reported [20]. Based on
the bacterial inhibitory results at the end of 24 hours
from the start of inoculation of bacteria with maggot
extracted ES, the optimum technique was adopted. This
technique was implemented in the present study and
briefly described in the following paragraph.
L. cuprina blowflies were reared on raw meat in plexi-
glass cages under controlled humidity and temperature
conditions (25°C), at Medifly Laboratories, Nanyang
Technological University, Singapore. Eggs laid on the
meat were treated with 70% ethanol and sterile distilled
water successively three times. The treated eggs were
deposited on fresh meat and allowed to hatch to mag-
gots for 2-3 days in an incubator at 35°C (see Figure 1).
Late second/early third instar maggots were aseptically
Figure 1 Rearing of Lucilia cuprina maggots. (a) Maggots eggs.
(b) Late second instar maggots obtained at the end of day two of
incubation (at 35°C) of eggs on the meat.
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and sterile distilled water successively three times and
soaked in filter paper. Treated maggots were transferred
to a 15 mL sterile tube with PBS, to a density of 100 lar-
vae per 200 μLo fP B S .T h e yw e r ea l l o w e dt oi n c u b a t e
in the test tube in dark at room temperature (25°C) for
1 hour. Resultant maggot ES obtained was transferred to
another tube using a pipette and autoclaved for 20 min-
utes at 121°C. Subsequently, the ES was allowed to cool
to room temperature. Any remaining ES was stored at
-20°C for analysis and future use.
The extracted ES was made to undergo gas-chroma-
tography and mass-spectrometry (GC-MS) analysis to
test the presence of previously suggested antibacterial
compound, phenylacetaldehyde [26]. The tests were
performed on a gas chromatograph (GC, Agilent
7890A) and mass spectrometer (MS, 5975C MSD)
using a HP-5MS analytical column. The GC was fitted
with a manual splitless injector, which was maintained
at a temperature of 250°C. The complete parameters of
the GC are summarized in Table 1. The mass spectro-
metry scanning was done across the range of m/z
35-450. The temperature at the inlet was maintained
at 280°C to prevent condensation of the analytes. The
parameters for the MSD are summarized in Table 2.
The compounds detected by the mass spectrometer
were compared in structure to those in the Nist98
database for mass spectral peaks and standard solution
peaks.
The pH of the collected ES was also measured using a
bench top pH meter (Fisher Scientific, Singapore)
against PBS reference and standards of pH 7 and 10.
The MIC for the maggot ES was determined similarly,
by broth microdilution method using the bacteria and
ES mixture by further PBS serial dilution [24].
Micro-device tests with ES and ciprofloxacin on S. aureus
Overnight MSSA cultures were sub-cultured in IS
broth to a standard inoculum of 0.5 Macfarland
turbidity [25]. 50 μL of this inoculum was added to
200 μL of sterile ES (collection explained in the pre-
vious section) and vortexed thoroughly. The mixture
was injected into a sterile micro-device from both the
inlets to fill the six wells (wells 2 to 7, see Figure 2) to
25 μL. Subsequently, ciprofloxacin at a working con-
centration equal to the MIC, determined earlier, was
injected from one inlet and sterile PBS from the other,
simultaneously, filling each well to a total volume of
50 μL. The resultant antibiotic concentration in the
wells of the microchip was then 100%, 80%, 60%, 40%,
20% and 0% of ciprofloxacin MIC (see Figure 2). The
inoculated micro-device was incubated in the box
incubator of the system at 37°C for 24 hours [23].
Optical density (OD) was measured at the start of the
experiment, then after 8 hours and finally at 24 hours.
The OD was later translated to bacterial count in
CFU/mL using the translation OD-cell count curve
previously determined for MSSA in similar experi-
ments [20]. The starting bacterial concentration was
determined by performing plate counts of viable colo-
nies at the start of the experiment and then after
24 hours. The cell count (in CFU/mL) was plotted
against time to seek a combination of the antibiotic
and ES that showed enhanced antibacterial activity
Table 1 Gas Chromatograph control parameters
Gas Chromatograph Agilent 7890A
Analytical Column HP-5MS (30 m × 0.25 mm × 0.25 mm)
Injection Port Type Manual Split/Splitless
Injector Temperature 250°C
Pressure 11.567 psi
Injector Type Split
Split Ratio 200:1
Split Flow 200 mL/min
Gas saver OFF
Total flow 204 mL/min
Carrier Gas Helium
Oven program Temperature Hold Time Rate
40°C 1 min
280°C 5 min 10°C/min
Table 2 Mass spectrometer control parameters
Mass Spectrometer 5975C MSD
GC inlet line temperature 280°C
MS quad temperature 150°C
Full scan range m/z 35-450
Solvent delay 0.1 min
Figure 2 Microfluidic device: Micro-device with well and inlet
markings.
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tration without ES.
A control was also performed without ES simulta-
neously on a separate device. The antibiotic and PBS
were similarly injected from the inlets of device, so that
each well had similar ciprofloxacin concentrations
explained earlier, but without the ES. OD and plate
counts were recorded at the same time intervals as in
previous experiments.
Plate counts obtained at 24 hours were compared with
the initial bacterial concentration and a relative reduc-
tion of viable bacteria after incubation with drugs was
determined. The results were plotted against concentra-
tion of ciprofloxacin, with and without ES. The results
were also compared to each other and with the control
in decreasing concentration of ciprofloxacin.
To assess the effects of ES on development of adap-
tive ciprofloxacin resistance in S. aureus, the bacteria
was exposed to ciprofloxacin at MIC concentration,
with and without the addition of ES, continuously for
six days (144 hours). The experiments were performed
in the micro-device, by injection of ES in PBS followed
by ciprofloxacin (= MIC) from both inlets. The resul-
tant solution in each well of the micro-device would
thence have same concentration of ES and ciprofloxa-
cin. The control was prepared separately in 96-well
plate for comparison of results. The exposed inocula
were analysed after every 24 hours, by diluting and
plating 10 μL of sample from each well and counts
were averaged. The drugs and media were replenished
after every 24 hours.
Results
MIC of ciprofloxacin and Maggot ES
The bacteria showed susceptibility to ciprofloxacin at
concentration 1 μg/mL. However, there was no visible
antibacterial activity observed in the diluted ES forms in
the MIC assay, as all the wells were turbid after over-
night incubation. However, the original ES was able to
show bacterial reduction up to 30% (±10%) from the
starting bacterial concentration as also revealed in the
time-kill analysis previously conducted [20].
GC-MS and pH of maggot ES
The qualitative GC-MS analysis of the maggot ES, estab-
lished the presence of the antibacterial compound, phe-
nylacetaldehyde. The test peaks were compared with
those of commercially procured phenylacetaldehyde
(≥ 90%, Sigma, Singapore) standard peaks. The quantita-
tive analysis determined an average of 84.5 mL/L (±7.23
mL/L) of the antibacterial compound in the ES. The pH
of the ES was in the range of 8.6-8.7 for all samples
collected.
Micro-device drug combinations
The data on bacterial growth in the micro-device was
recorded at 0, 8 and 24 hours after MSSA suspension
was exposed to drug and drug combinations.
The graphs in Figure 3 illustrate CFU/mL versus time
functions in different wells of the inoculated micro-
d e v i c e .F r o mt h eg r a p h s ,i tc a nb en o t e dt h a t ,w i t h
ciprofloxacin at MIC and sub-MIC concentrations, there
is significant bacterial growth at all concentrations after
24 hours. The only exception was at 100% concentra-
tion, where bactericidal effect was observed. Whereas,
with ciprofloxacin in combination with maggot ES,
though no significant growth inhibition was observed in
Well 7, (100% ES concentration), stunted growth was
observed in ES with 80 and 60% ciprofloxacin. Compar-
ing with 60% and 80% ciprofloxacin only, it can be
deduced that the addition of maggot ES helped to
enhance or potentiate the activity of ciprofloxacin at
sub-MIC levels.
The micro-device OD results were verified further by
plating the 24 hour samples from all the wells onto IS
agar plates to determine the bacterial concentration
(CFU/mL). The percentage reduction was calculated as
relative Log10 reduction from the starting bacterial
inoculum concentration and plotted (Figure 4).
From the graph in Figure 4, stunted bacterial growth
can be observed when maggot ES was used alone without
ciprofloxacin (30% growth reduction). However, in com-
bination with ciprofloxacin (at 80% and 60%) the maggot
ES show significant reduction, of up to 50% from the
starting inoculum concentration. When compared with
ciprofloxacin at corresponding concentrations, the reduc-
tion observed was less than 5% or no reduction.
The percentage reduction of bacterial number, calcu-
lated over the six day period of continuous exposure of
S. aureus to ciprofloxacin alone and in combination
with maggot ES, is summarized in Figure 5. It was
observed form the initial trials, that addition of maggot
ES was able to inhibit bacterial growth even after
72 hours of exposure, where ciprofloxacin alone failed
to inhibit at MIC concentration. This can be clearly
seen at the 144
th hour, where ciprofloxacin show no
reduction in bacterial growth, while stunted growth with
52.26% (±10%) reduction was observed with ES addition.
Similar reduction was seen on the subsequent days, in
the strains exposed to maggot ES and ciprofloxacin
combination.
Discussion
In the previous study with L. cuprina maggot ES, the
antibacterial activity that was observed, only showed
stunted growth of S. aureus after 24 hours [20]. In this
study, the qualitative and quantitative analysis of the ES
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Page 4 of 8Figure 3 CFU/mL vs. time functions for S. aureus with ciprofloxacin alone and in combination with ES. Readings directly taken from the
micro-device wells. (a) CFU/mL vs. time, when only ciprofloxacin and PBS were injected from the two inlets of the micro-device. (b) CFU/mL vs.
time, when ES with bacterial suspension was injected from both inlets, followed by ciprofloxacin and PBS from the inlets of the micro-device.
(The coefficient of variability (R
2) in the predicted data points from the translation of OD to CFU/mL graph was determined by linear regression
modeling. The value of R
2 was calculated as 0.9024, for all predicted CFU/mL values from recorded OD values). Each calculated data point has
±10% linear error value for cell number in CFU/mL. The OD was recorded in triplicates in three separate micro-devices for each day. The
experiments were repeated three times.
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antibacterial compound suggested previously to be
secreted by the maggot midgut commensals [8]. The
combination of ES with ciprofloxacin, as seen from the
results, was able to enhance ciprofloxacin activity at
sub-MIC levels. To some extent, the ES addition was
also able to demonstrate a good prospect in delaying the
process of development of resistant bacteria in the pre-
sence of antibiotic, for which adaptive resistance was
observed otherwise. However, with the density of mag-
gots used in the present study (50 maggots/100 μLo f
PBS), total bactericidal effects could not be detected as
s h o w ni np r e v i o u ss t u d i e sw i t hL. sericata maggots
[11,15,16]. The methods adopted for collection of the
ES in those studies were also different from the method
described here with L. cuprina maggots.
Ciprofloxacin acts on S. aureus by disrupting the DNA
replication mechanism. Its target, DNA gyrase is shown
previously to undergo adaptive mutation when exposed
to ciprofloxacin at near MIC concentrations. This may
take place in as few as 4 days of drug exposure [22]. A
point mutation in the subunits of the DNA topoisome-
rase enzyme (grlB gene), resulting in a resistant specie
was reported by Stutandar et. al. [22], when they
exposed S. aureus at near-MIC of ciprofloxacin. Similar
point mutations have been demonstrated by others
[27,28]. This kind of emergence of resistant bacterial
species, due to antibiotic use, over use or abuse over
time has become a major concern in the healthcare
sector [29]. The emergence of multi-drug resistant
MRSA in hospitals and chronic wounds, motivate the
search for complementary, alternative and more effective
antimicrobial solutions. Even stronger and newer anti-
biotics such as vancomycin, have given rise to resistant
species over past few years [30]; coupled with the side
effects and dose related toxicities associated with their
use, it has encouraged research into alternative
remedies.
Maggot secretions and excretions possess antibacterial
activity against a wide range of pathogens as shown in
previous studies and in their wound healing capabilities
in biosurgery [2,11,15,16]. Bexfield and co-workers [11],
purified and separated the maggot excretions based on
their molecular weights by ultrafiltration. The low mole-
cular weight fractions (5-10 kDa and <500 Da) of the ES
demonstrated significant antibacterial activity against
S. aureus. The fractions were also found to be heat stable,
suggesting non proteineceous and non enzymatic factors.
Recently, Cerovsky et. al.[19], isolated and purified a
defensin peptide from the maggots of L. sericata,t h a t
coincided with the results of Bexfield et. al. This peptide,
lucifensin, was reported to have molecular weight in the
range of 5-10 kDa and exhibited antibacterial activity
against a number of bacteria [19]. These low molecular
weight defensin peptides are known to give insects their
intrinsic ability to fight against pathogenic invaders as
they possess antimicrobial properties [31]. They are also
Figure 4 Percentage reduction graph for 24 hr study.
Percentage reduction from the initial bacterial concentration at ‘0
hour’ calculated after 24 hours of exposure of MSSA to ciprofloxacin
at MIC and sub-MIC concentration and maggot ES in combination
with ciprofloxacin at various concentrations. The cell number was
calculated over a range of dilutions and averaged. Each dilution was
plated in triplicates for zero and 24 hours. The combination
experiments were repeated seven times with ES collected on the
day of experiment.
Figure 5 Percentage reduction graph for 144 hr study.
Percentage reduction from the initial bacterial concentration at ‘0
hour’ calculated every 24 hours of exposure of S. aureus to
ciprofloxacin at MIC and maggot ES in combination with
ciprofloxacin at MIC, for 144 hours (six days). The cell number was
calculated over a range of dilutions and averaged. Each dilution was
plated in triplicates for zero and 24 hours. The values of cell number
obtained from each of the six wells of the micro-device were
averaged for calculations.
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[32,33]. For this reason, maggot debridement therapy is
particularly useful for the treatment of wounds infected
with hospital-acquired MRSA. The results have been
demonstrated by Beasley and Hirst in their study of
wounds infected by multi-drug resistant MRSA [8].
Several mechanisms of wound disinfection by maggots
have been proposed in the past. One of the suggested
mechanisms is by simple mechanical irrigation of
wound by increased exudate, caused by ingestion of
liquefied necrotic tissues by the larvae. This results in
wound lavage and dilution of bacterial concentration
over the wound [1,8]. Some have suggested excretion of
ammonia that increases the pH of the wound, making it
unfavourable for many bacterial species to survive. The
ES collected in this study also exhibited alkaline pH
value, supporting the previous findings. Some have even
suggested ingestion of bacteria by the larvae during
wound irrigation, followed by their digestion as they
pass through the digestive tract of the maggots. Mum-
cuoglu et. al.[ 1 7 ] ,i nt h e i rw o r k ,d e m o n s t r a t e dt h e
destruction of ingested bacteria in the midgut of mag-
gots. Maggots are also known to secrete antibacterial
compounds such as phelyacetaldehyde and phenylacetic
acid, that are secreted by the midgut commensals of
maggots, P. Mirabilis [8,34].
Besides identification of the antibacterial factors in the
ES, the current study was also able to show potentiation of
ciprofloxacin activity at sub-MIC concentrations in combi-
nation with maggot ES in the 24 hour study. In general,
the use of antibiotics in combination from the start may
help to reduce the events of development of resistance in
a pathogen [35]. Moreover, hypothetically, if the density of
t h eE Sp r e p a r a t i o nc o u l db ei n c r e a s et h e r ew o u l db e
improved bactericidal effects. However, practical con-
straints to rear large number of maggots limited that pos-
sibility. Therefore, a combination therapy could be
potentially useful and considered in appropriate situations.
The further study on survivability of S. aureus in presence
of both ciprofloxacin and insect extract for 144 hours,
demonstrated high growth reduction compared to cipro-
floxacin exposure alone. The adaptive resistance could be
observed in the fourth day of exposure to ciprofloxacin
alone (after 96 hours), where less reduction in bacteria
number (~ 30% reduction) was seen. In the following days,
the reduction in the ciprofloxacin exposed strain reduced
to 5%, followed by no reduction. Whereas, with added ES,
the reduction was maintained at more than 50% through-
out the six days of the study. This clearly suggested an
inhibition of adaptive resistance development in the
exposed bacteria by ES addition as a potentiating or resis-
tance modifying agent. Further determination of resistance
profiles of MSSA by molecular and other methods, under
the influence of the combination would give detailed
insights into the potentiating activity of the insect extract.
Conclusions
The present study shows that ES extracted from mag-
gots of L. cuprina in combination with ciprofloxacin
antibiotic at concentrations of 80 and 60% of MIC,
demonstrate up to 50% reduction in bacterial number
from the starting inoculum concentration, after
24 hours of exposure. The outcome of the 144 hours of
exposure of the bacteria to the ES-ciprofloxacin combi-
nation, suggested a potential delay in the development
of adaptive resistance to the antibiotic. The results
clearly suggest a potentiation of the antibiotic activity.
The ES was analyzed by GC-MS, and revealed the pre-
sence of antibacterial compound, phenylacetaldehyde
and had an alkaline pH. Both these findings support the
antibacterial activity of the ES. The study was carried
out in a system designed to perform separation and
mixing of two fluids in various concentrations whilst
performing culturing, sustaining and monitoring cells in
a favorable growth environment.
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